Closed Loop System With Pramlintide Versus Exenatide (Closedloop)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01269008
Recruitment Status : Completed
First Posted : January 4, 2011
Last Update Posted : February 20, 2018
Information provided by (Responsible Party):
Rubina Heptulla, Albert Einstein College of Medicine, Inc.

Brief Summary:

Post-prandial hyperglycemia occurs despite meticulous carbohydrate counting and rapid acting insulin therapy. Furthermore, this occurs even in the setting of the closed loop system. Currently the algorithm used for calculating the glucose-responsive insulin delivery cannot respond in a timely fashion to the glucose absorption resulting from a meal. In diabetes, there is paradoxical immediate post-prandial hyperglucagonemia that results in immediate post-prandial hyperglycemia. Amylin deficiency and/or dysregulated GLP-1 seems to be the etiology. Pharmacologic replacement of these hormones alleviates immediate post-prandial hyperglycemia in diabetes. With this protocol, the investigators would like to optimize treatment of T1DM by physiologic replacement of hormones in addition to insulin and in the process also optimize the insulin algorithm.

This is a paired, randomized, and controlled comparison of pramlintide and insulin versus exenatide and insulin Vs insulin monotherapy using the ePID closed-loop system for insulin delivery.

The investigators will stratify the study subjects into the following sub-groups of 5 subjects of 22-30 years old, 4 subjects of 18-21 years old, 4 subjects of 16-18 years old. The investigators would also begin the study with the 21-25 year patient sub-group and then transition to the other sub-groups after evaluating all the safety issues. 22-30 year old ones would be considered as an adult subset, 18-21 year olds would be considered pediatric subset according to the guidelines of FDA's Center for Devices and Radiological Health (CDRH) and 16-18 year olds are considered typical pediatric population. At this time, Spanish-speaking subjects will not be recruited because Medtronic Minimed as yet does not have any literature in Spanish that may used in explaining the study to this group of patients. When in the future Medtronic is able to provide us with the appropriate Spanish literature, the investigators will at that time amend the protocol to include this group of subjects.

Condition or disease Intervention/treatment Phase
Type 1 Diabetes Device: Medtronic ePID 2.0 Phase 1

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : December 2010
Actual Primary Completion Date : January 2013
Actual Study Completion Date : January 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Intervention Details:
  • Device: Medtronic ePID 2.0
    Closed loop system is an automated insulin delivery system based on body blood sugar. It consists of an Insulin pump, glucose sensor, and a device presently a laptop with all the algorithms.

Primary Outcome Measures :
  1. Better meal and post meal sugars on the closed loop device using the study medications. [ Time Frame: 18 months ]
    We will assess the preliminary data collected from the subjects enrolled by that time

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 30 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age greater than 18 years and less than 30 years.
  2. Have had diabetes for at least 1 year, and in good control (HbA1C less than 8.5 %).
  3. Be on continuous subcutaneous insulin infusion using an insulin pump
  4. Subjects must be otherwise healthy except for T1DM, and treated for hypothyroidism if present
  5. Menstruating women must have negative pregnancy test.
  6. Hemoglobin (Hb) more than 12 g/dl
  7. Weight must be equal to or greater than 50 Kg

Exclusion Criteria:

  1. Any chronic disease (leukemia, asthma, inflammatory bowel disease, cystic fibrosis, juvenile rheumatoid arthritis, etc that directly, or as a result of treatment, directly or indirectly affect glucose homeostasis).
  2. Hemoglobin less than 12 g/dl
  3. Lack of a supportive family environment
  4. Positive pregnancy test based on serum beta HCG in menstruating young women
  5. Evidence or history of chemical abuse
  6. HbA1c more than 8.5 %
  7. Weight less than 50 Kg
  8. History of gastroparesis and on medications that alter gastric emptying
  9. History of Pancreatitis and impaired renal function
  10. Hypoglycemic unawareness
  11. History of sensitivity to 5-HT3 receptor antagonists
  12. History of QT prolongation
  13. Concomitant use of both Acetaminophen and vitamin C
  14. Patients on glucocorticoid therapy
  15. Known allergies to any of the study medication

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01269008

United States, New York
Albert Einstein College of Medicine CRC
Bronx, New York, United States, 10461
Sponsors and Collaborators
Albert Einstein College of Medicine, Inc.
Principal Investigator: Rubina A Heptulla, MD Albert Einstein College of Medicine, Inc.

Responsible Party: Rubina Heptulla, Division Chief of Pediatric Endocrinology & Diabetes, Albert Einstein College of Medicine, Inc. Identifier: NCT01269008     History of Changes
Other Study ID Numbers: 2010 -434
First Posted: January 4, 2011    Key Record Dates
Last Update Posted: February 20, 2018
Last Verified: February 2018

Keywords provided by Rubina Heptulla, Albert Einstein College of Medicine, Inc.:
Closed loop
type 1 diabetes
insulin pump

Additional relevant MeSH terms:
Diabetes Mellitus, Type 1
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists